Page 1

H1N1 - Panvax

Swine Flu Vaccination

Vince Rettura

Delivering a Healthy WA

24 September

2009

Slide 2

Final changes…….next 9 slides

provides an overview of the main

changes

24 September

2009

Slide 3

What are the Changes………

Vaccination of Children

• At present, Panvax H1N1 vaccine is not approved for

use in children under the age of 10 years.

• Clinical trials in children have not yet been

completed but information from these trials should

be available towards the end of 2009

• Health professionals will be notified when the

vaccine has been approved by the TGA for use in

children under the age of 10

24 September

2009

Slide 4

Multi Dose Vial

• Panvax H1N1 vaccine packed in blue boxes with blue

labels contains 18 doses per 10ml vial

• Panvax H1N1 vaccine packed in red boxes with red

labels contains 10 doses per 5 ml vial

• Each box of vaccine will contain stickers detailing

batch number and expiry. These stickers can be

affixed to consent forms an in paper patient records

– these are not compulsory to use

DOSAGE

• The dosage for adults and children aged 10 years and over is

15ug in 0.5mls as a single dose.

24 September

2009

Slide 5

Pre-filled syringes

• Single-dose pre-filled glass syringes, complete with

needle for injection, are anticipated to become

available for use in young children once the TGA has

approved Panvax H1N1 for use in this age group.

Use with other vaccines

• There are no data available to assess the

concomitant administration of Panvax H1N1 vaccine

with other vaccines

• If Panvax H1N1 vaccine is to be given at the same

time as another injectable vaccine, the vaccines

should be given at different injection sites.

24 September

2009

Slide 6

Administration

• The vaccine should be administered by

intramuscular or deep subcutaneous injection

Clinical trials

• Clinical data specific to Panvax® H1N1 Vaccine show that the

vaccine is safe and well tolerated in adults ≥ 18 to < 65 years of

age.

• A total of 240 participants were administered a single dose of

vaccine containing 15 μg or 30 μg HA.

• The most common solicited local (injection-site) adverse events

observed within 7 days of administration of the vaccine were

injection-site tenderness, pain and induration, with the majority

of reactions of mild intensity and self-limiting.

24 September

2009

Slide 7

• The most common solicited systemic adverse

reactions were headache, myalgia and malaise, with

the majority of these events mild to moderate in

intensity and similarly self-limiting

• In addition, headache was identified as the most

common unsolicited adverse event, reported in 11.7

% of participants.

• Other unsolicited adverse events, reported by more

than 2 % of participants, were back pain, arthralgia,

seasonal allergy, cough, oropharyngeal pain, nasal

congestion, diarrhoea and toothache.

• There were no reports of serious adverse events.

24 September

2009

Slide 8

GUILLAIN-BARRÉ SYNDROME

• There have been reports of a possible association

with swine influenza vaccination and the

development of Guillain-Barré syndrome (GBS).

• Whether this is causal or only a temporal association

is unclear.

• Viral and bacterial infections, especially

Campylobacter jejuni and acute respiratory tract

infections are the commonest antecedents of GBS.

• The estimated frequency of influenza-related GBS is

four to seven times higher than the estimated

frequency of influenza vaccine-associated GBS.

• If there is a causal association with influenza

vaccine it is of the order of 1-2 per million people

vaccinated.

24 September

2009

Slide 9

THIOMERSAL

• Panvax® H1N1 vaccine has been formulated in multi-

dose vials containing the preservative, thiomersal.

• Thiomersal, which contains a small amount of

mercury, has been used in medical products and

vaccines for more than 60 years and is the most

commonly used preservative in multi-dose vials. It

has a very long safety record.

• Thiomersal was removed from vaccines given to

young children in Australia as a precaution to reduce

the theoretical risk of exposure to mercury in babies,

particularly those of very low birth weight.

24 September

2009

Slide 10

• However, there is no evidence that thiomersal

in vaccines has caused any developmental or

neurological abnormalities, such as Attention

Deficit Hyperactivity Disorder (ADHD), autism

or any other health problem.

• Following a recent review of the evidence,

ATAGI has advised that influenza vaccines

containing thiomersal are considered safe.

Full details of ATAGI’s advice will be made

available on the

www.healthemergency.com.au website in the

near future.

24 September

2009

Slide 11

• It is now recommended to draw up the

vaccine from MDV with a 23g x 38mm needle

instead of a 19g needle

Vaccine drawn up and stored in syringes

• Once vaccine has been drawn up from MDV and into

syringes, it must be used within 4 hours. After 4

hours syringes must be disposed of.

Drawing up needles

24 September

2009

Slide 12

Goal

• The goal of the pandemic vaccination

program is to provide protection to the

pandemic virus by vaccinating as many

people as quickly as possible, using an

approach which targets specific population

groups

24 September

2009

Slide 13

Rationale

The underlying principles for targeting groups in Australia

include:

• To prevent severe disease in those vulnerable to more

severe outcomes

• To prevent spread of disease to the vulnerable by

vaccinating their contacts

• To protect those at high risk of exposure because of their

work

• To protect health care services and reduce healthcare

worker staff absenteeism

• To mitigate potential economic impact on the Australian

pig industry

• To provide herd immunity

24 September

2009

Slide 14

Priority Tiers

First Tier

•Pregnant women

Some women who have caught

H1N1 have miscarried or gone

into premature labour

•Medically at risk- vulnerable

population

•Health care workers

•Indigenous

Second Tier (early 2010)

•Children not covered by 1st tier

aged 6 months < 10years

•School aged children

24 September

2009

Slide 15

Age cut offs in Priority Tier One

• Indigenous People - All people aged 10 years and

older will be included

• Vulnerable (including medically at risk) - All people

aged 10 years and older will be included

There is no older age cut off proposed.

24 September

2009

Slide 16

Defining of Health care workers

• HCW: An employee, student or volunteer who has direct contact

with patients, either in the community or at a dedicated health

service sited, in both public and private sectors limited to the

following:

• Aboriginal medical services

• General practice

• Ambulance services (includes RFDS)

• Remote or community health clinics and nursing posts

• Hospitals

• Prisons

• Satellite dialysis units

• Post acute care services in the home (eg silver chain)

24 September

2009

Slide 17

• Community care workers: an employee,

student or volunteer who has direct contact

with patients, either in the community or at a

dedicated site, limited to the following:

• Aged care

• Disability services

24 September

2009

Slide 18

Who gets the vaccine directly?

•Metropolitan Public

Hospitals

•Regional Hospitals

•Private Hospitals and Day

Surgeries

•St Johns Ambulance

•Prisons

•Community Health

Clinics

•GP surgeries

•Residential Aged Care

Facilities

•Disability Service

Facilities

•RFDS

•Private satellite Dialysis

Units

•Public Satellite Dialysis

Units

•Aboriginal Medical

Services

24 September

2009

Slide 19

• Vaccine ordering and delivery is as per usual

ordering mechanisms for those recipients

listed under “who gets the vaccine directly”.

24 September

2009

Slide 20

• As this is a new strain of the influenza A virus,

most people do not have any natural immunity

so they are more likely to catch this new ‘flu’

then they are to catch the seasonal flu.

• This vaccine will prevent those with

underlying medical conditions from

developing severe illness

Why do people need to be

vaccinated

Product Information

•Information provided may change!

•Refer to the first 9 slides for

Commonwealth changes

24 September

2009

Slide 22

Which vaccine is to be used to treat

H1N1 Pandemic Influenza?

24 September

2009

Slide 23

Panvax H1N1 monovalent

Vaccine - CSL

Panvax is a vaccine which

has been made to provide

immunity to the pandemic

2009 influenza strain of

the influenza A virus – a

new strain of the

influenza A virus

24 September

2009

Slide 24

Product Description

Panvax is supplied as:

• a clear liquid in

• 10ml Multi dose vials with a latex free rubber

stopper

• Vaccine for children less than 10 years of age

will be provided in single dose pre-filled

syringes (thiomersal free) once approved by

the TGA

• Boxes of 10 vials or may come to start with

boxes of 50 vials .

24 September

2009

Slide 25

24 September

2009

Slide 26

What’s in Panvax?

Vaccine

Specifications:

24 September

2009

Slide 27

The basic vaccine formulation is as

follows:

• Monovalent vaccine

• 15ug of antigen per 0.5mls

• Unadjuvanted (Adjuvants are compounds used to

enhance the immune response to vaccination – The

use of adjuvanted vaccines on a large scale carries

the risk that previously unrecognised side effects will

occur. That the risk is increased if the adjuvant has

not been widely used in man or has not previously

been combined with influenza antigens)

24 September

2009

Slide 28

• 10ml Multi Dose Vials (containing thiomersal

– compound partly composed of mercury and

ethylmercury.

- Used to prevent bacterial and fungal

contamination of vaccines

24 September

2009

Slide 29

Causes a toxic effect after it reaches a

certain level in the body

• Whether or not it reaches a toxic effect after it

reaches a certain level in the body depends on

- the amount of mercury consumed and

- the persons body weight.

• Individuals with very low body weight are usually

more susceptible to toxic effects from a certain

intake of mercury. HENCE…….

• Vaccine for children less than 10 years of age will be

provided in single dose pre-filled syringes

(thiomersal free) once approved by the TGA

24 September

2009

Slide 30

According to the Commonwealth

• There is no evidence that thiomersal has

caused any developmental or neurological

abnormalities, such as ADHD or Autism

24 September

2009

Slide 31

Other components According to

Product Information– Each 0.5mls

contains

• Sub units of A/California/7/2009 (H1N1) v-like

virus

• 15ug haemagglutinin

• As stated – 0.01%w/v Thiomersal as a

preservative

24 September

2009

Slide 32

Each 0.5mls also contains

• Sodium Chloride 4.1mg

• Sodium phosphate –dibasic anhydrous 0.3mg

• Sodium phosphate- monobasic 80ug

• Potassium chloride 20 ug

• Potassium phosphate – monobasic 20 ug

• Calcium chloride 1.5ug

Explanation of contents in Appendices in 9th ed

handbook under Vaccine Content

24 September

2009

Slide 33

The following are present per dose:

• Taurodeoxycholate ≤ 5ug (Bile salt-related, anionic

detergent) (can give red eyes, blurred vision etc)

• Ovalbumin ≤ 1.0ug

• Sucrose <10ug

• Neomycin ≤ 0.7ug – check for allergies to this antibiotic

• Polymyxin B sulfate ≤0.11ng– check for allergies to this antibiotic

• Beta-propiolactone ≤1.4ng

24 September

2009

Slide 34

Dosage and Administration

24 September

2009

Slide 35

Take note……..

• Previously -- The vaccination course

consists of 2 doses of 15ug of antigen

at least 21 days apart. … This now no

longer applies

• The vaccination course consists of

1 dose of 15ug of antigen 0.5mls

for those aged 10 years of age and

older

24 September

2009

Slide 36

• Children aged 6 months to <9yearsof

age require 2 doses with a minimal

interval of 21 days. This will be

available once the TGA has approved

the vaccine for this age group

24 September

2009

Slide 37

Name

Doses

Tier of

administration

1st dose

2nd dose

Minimum

interval

between

doses

Panvax 1 (One) IM

dose

(0.5ml/dose)

10 years and

older

Can now be given

by deep sub

cutaneous

injection

TIER 1

Pregnant

women

Medically at

risk (10 years

of age and

over)

Health care

workers

Indigenous

( 10 years of

age and over)

Pregnant

women in

their 2nd and

3rd trimester

Individuals

aged 10

years old and

over will be

able to

receive this

formulation

of 15ug of

antigen per

0.5ml

Nil for

those 10

years and

over

Can give in

1st

Trimester

That is for

eg. given

accidently

not

knowing if

client was

pregnant

Or if client

requests it.

Nil for

those 10

years and

over

24 September

2009

Slide 38

Please Note -- CHANGES

• All children under 10 years of age will have to

wait for the thiomersal free vaccine once

approved by the TGA

24 September

2009

Slide 39

Use with other vaccines?

• Panvax can be given with other vaccines

• It is not a live vaccine so no special waiting

times when administering other vaccines

• If Panvax H1N1 vaccine is to be given at the

same time as another injectable vaccine, the

vaccines should be given at different

injection sites.

24 September

2009

Slide 40

How much is given?

• 1 (One) IM or deep

sub cut dose (0.5ml/dose)

10 years of age and over

24 September

2009

Slide 41

Administration and instructions for

use and handling

• Panvax is for IM or deep subcut injection

• Vaccine that has been drawn into syringes in

preparation for administration must be used

within 4 hours

• Punctured Multi Dose Vials can remain in the

fridge for up to 24hours since date of first

opening (may change)

24 September

2009

Slide 42

• Check and observe vial for clear fluid

• The contents of the vial should be inspected visually

before and after shaking for any foreign particulate

matter and or abnormal physical appearance prior to

administration

• Once drawn up into a syringe it is for single use only

• ALSO - once drawn up into syringe – must be

discarded at the end of the day/clinic etc DO NOT

STORE DRAWN UP SYRINGES FOR NEXT CLINIC

DAYS AND DO NOT DRAW UP VACCINE FOR THE

WHOLE WEEK OR FOR NUMEROUS VACCINATION

CLINICS! It only has a life span of 4 hours in a

syringe

24 September

2009

Slide 43

Preparing Panvax

24 September

2009

Slide 44

•Record the date and time of opening on

the MDV

DO NOT USE MDV if:

-sterility is breached

-cold chain is breached (outside 2-8°C)

-expiry date reached

-More than 24 hours since date of first

opening (may change again) and

contact_________________________

for advice on how to discard (see cold

chain section)

•Wipe the diaphragm of the MDV

with an alcohol swap

•If taking doses from an already

opened MDV, check opening date

and then wipe the diaphragm with

alcohol prior to use

ONE

TWO

24 September

2009

Slide 45

•Using an aseptic ‘no-touch’

technique, insert into the diaphragm a

new single use sterile drawing up

needle for the extraction of doses

•Draw up each single dose required

into separate new sterile syringes

and attached a new sterile

administration needle

•Each single dose vaccine must be

used (within 4 hours of drawing up

vaccine) and/discarded after 4

hours

THREE

FOUR

24 September

2009

Slide 46

•When the required number

of doses have been

extracted, remove the

drawing up needle and

dispose in appropriate

sharps container

•If contents of the MDV are

not all used, refrigerate the

MDV (+2-8°C)

NB: Unused vaccine

should be discarded

through normal medical

waste mechanisms

FIVE

SIX

24 September

2009

Slide 47

• Gloves are not recommended for routine

immunisation service providers. However, in

a pandemic influenza environment, PPE -

mask, eyewear, gloves and gown may be

indicated for protection of the vaccine

administrator if need be.

24 September

2009

Slide 48

Vaccine distribution

• First delivery of vaccines – Contact the 9388

number on the order form if you require more

vaccines on your first order

• 50 pack of 10ml vials = 18-20 doses per vial

• 10 pack of 10ml vials = 18-20 doses per vial

• End of September delivery changes

• 10 pack of 5ml vials = 10 doses per vial

24 September

2009

Slide 49

Cold Chain

• As per Strive for 5 Guidelines

• Store at +2-+8oC

• Refrigerate do not Freeze and protect from light

• If the vaccine has been exposed to a cold chain breach, do not

discard but isolate vaccines, inform other staff and label them

“Do not use”. Keep the vaccines stored at +2-+8°C and contact

________________________ for advice

• Cold chain breaches are to be reported through normal

channels of reporting. For eg. contacting the divisions of

general practice, Regional Immunisation Coordinators, the

Central Immunisation clinic etc in order to obtain advice.

24 September

2009

Slide 50

• If MDV is to be used throughout an immunisation clinic and left

on a work bench for easy access so you do not have to go into

the fridge repeatedly -

• - ensure that the MDV is placed within a kidney dish, protected

from light and the kidney dish is placed on top of an ice block to

maintain the cold chain.

• - drawn up vaccines can remain within the kidney dish whilst

vaccinating

• NB: always check the coldness of the cold pack an the cold

pack must be ‘sweated’ first upon removal from the freezer.

24 September

2009

Slide 51

Common Questions

24 September

2009

Slide 52

If I had Human Swine flu do I need to

be vaccinated?

24 September

2009

Slide 53

• If you have been diagnosed with swine flu –

confirmed by testing, then No vaccination is

required

• If you have been told you had swine flu but

not confirmed testing then you can get

vaccinated

24 September

2009

Slide 54

If someone was on Tamiflu can they

be vaccinated?

24 September

2009

Slide 55

Yes

• Tamiflu is an antiviral working on infections

24 September

2009

Slide 56

How long after the vaccination am I

protected

24 September

2009

Slide 57

• On average it takes about 2-4 weeks to fully

develop protection against Human Swine Flu

24 September

2009

Slide 58

How long am I protected??

24 September

2009

Slide 59

• 1 year protection

24 September

2009

Slide 60

Is the vaccine safe???

24 September

2009

Slide 61

• Clinical data specific to Panvax® H1N1 Vaccine show that the

vaccine is safe and well tolerated in adults ≥ 18 to < 65 years of

age.

• A total of 240 participants were administered a single dose of

vaccine containing 15 μg or 30 μg HA.

• The most common solicited local (injection-site) adverse events

observed within 7 days of administration of the vaccine were

injection-site tenderness, pain and induration, with the majority

of reactions of mild intensity and self-limiting.

• The most common solicited systemic adverse reactions were

headache, myalgia and malaise, with the majority of these

events mild to moderate in intensity and similarly self-limiting

24 September

2009

Slide 62

Can Thiomersal be given to pregnant

women?

24 September

2009

Slide 63

• YES

• Thiomersal has a very long safety record and has not

been shown to have any long term problems

• Influenza vaccines are safe during pregnancy and are

normally recommended for pregnant women. The

Panvax® H1N1 vaccine is not a ‘live’ vaccine and is

not a risk to unborn babies.

• Expectant mothers may have some side effects from

vaccination but this is usually only a sore, red arm,

or slight headache.

24 September

2009

Slide 64

• Following a recent review of the evidence,

ATAGI has advised that influenza vaccines

containing thiomersal are considered safe.

Full details of ATAGI’s advice will be made

available on the

www.healthemergency.com.au website in the

near future.

24 September

2009

Slide 65

If I had the seasonal flu do I need to

get this additional vaccine (even

during pregnancy?) ?

24 September

2009

Slide 66

• Yes

• This new vaccine protects people against

pandemic influenza – Human Swine Flu.

• The seasonal vaccine gives no protection

against this new strain

Who should not get the

vaccine?

Children under the age of 10 cannot

be vaccinated with Panvax H1N1

vaccine as it is not approved for use

by the TGA

24 September

2009

Slide 68

People with a known severe allergy to eggs

should not be given the vaccine ---

(anaphylactic hypersensitivity)

Characterised by

• Generalised hives

• Swelling of the mouth and throat

• Difficulty in breathing, wheeze

• Low BP and

• Shock

24 September

2009

Slide 69

• And as usual:

- Anaphylaxis following a previous dose of the

relevant vaccine, and

- Anaphylaxis following any component of the relevant

vaccine

• Also check allergies to:

- Neomycin

- Polymyxin B

- Especially if the client has had an anaphylactic

hypersensitivity to the above anti biotics

24 September

2009

Slide 70

Be aware of false contraindications

to vaccinations

• Conditions listed in Table 1.3.4 page 21 in the

Immunisation hand book outlines false

contraindications.

• People with these conditions should be

vaccinated with all recommended vaccines

24 September

2009

Slide 71

Corticosteroids – just take note...

• Clients on daily doses of corticosteroids (Adults in excess of

60mgof prednisilone; Children in excess of either 2mg/kg per

day for more than a week or 1mg/kg daily for 4 weeks) will

greatly suppress the immune system

• which means that not only is the vaccine unlikely to be

effective, but there is an increased chance of adverse events

occurring as a result of immunosuppression

• just like any vaccine you can still vaccinate however the

protection offered will be greatly reduced…….

- Partial protection is better than no protection. If the client

was to catch swine flu and was vaccinated --- the

symptoms may not be as severe

24 September

2009

Slide 72

What about other medication??

24 September

2009

Slide 73

• Some medications may interfere with

influenza vaccines as discussed.

• Others include:

- Some treatments for cancer (including

radiation therapy)

- Cyclosporine- immunosuppressant drug

24 September

2009

Slide 74

What are the side effects from the

vaccine?

24 September

2009

Slide 75

- Pain and redness at the injection site

- Drowsiness or tiredness

- Muscle aches

- Low grade fever

- Malaise

- Headache

Common side effects include:

24 September

2009

Slide 76

Very rare side effects

• Severe allergic reaction (anaphylaxis)

• Guillian-Barre Syndrome (nervous system

disorder featuring paralysis)

24 September

2009

Slide 77

History of Guillian-Barre Syndrome

(GBS)

• Risks and benefits of the influenza and H1N1

pandemic influenza vaccine should be

weighed against the potential risk of GBS

recurrence

• Specialist advice advised

• NB People with a history of GBS may be at

risk of recurrence of the condition following

influenza vaccine

24 September

2009

Slide 78

Will I get GBS from this vaccine?

• From the evidence collected by experts:

• GBS is 4 to 7 times more likely after an attack

of the actual flu than after the influenza

vaccine

• There have been reports overseas of a

possible association between influenza

vaccinations and GBS

24 September

2009

Slide 79

Hasn’t the pandemic flu peaked –

isn’t it too late for me to benefit from

the vaccine??

24 September

2009

Slide 80

• We don’t know that the pandemic has peaked

• Its never too late to gain immunity

• Experience from countries in the northern

hemisphere this year has also shown that

pandemic influenza can continue to spread in

the summer months

• Vaccination will protect you through summer

and into the flu season next year

24 September

2009

Slide 81

What adverse events should be

reported?

24 September

2009

Slide 82

• Any adverse event that the immunisation

service provider considers to be serious or

unexpected should be reported. Serious

adverse events are listed in Appendix 6 of the

Australian Immunisation Handbook 9th

Edition

http://www.health.gov.au/internet/immunise/p

ublishing.nsf/Content/handbook-appendix6

24 September

2009

Slide 83

Can patients report adverse events?

24 September

2009

Slide 84

• Yes

• Patients wanting to report an adverse event

can do so by submitting a report online

directly to the Therapeutic Goods

Administration at www.tga.gov.au, or by

calling the Pandemic Hotline on 180 2007.

24 September

2009

Slide 85

Pandemic (H1N1) 2009 Influenza

Vaccination Packs

24 September

2009

Slide 86

• This Pandemic (H1N1) 2009 VacPac (VacPac)

contains equipment sufficient for the

administration of 200 doses of pandemic

H1N1 2009 influenza vaccine (vaccine).

• A mini VacPac is only available for GP

surgeries and only includes syringes and

needles only

• The components of each VacPac are listed

below:

24 September

2009

Slide 87

Item

Quantity/Packaging

1mL syringes

1 box x 220 syringes

Drawing up needles 19g x 38mm

1 box x 44 needles

Injection needles 23g x 25mm

1 box x 200 needles

Injection needles 23g x 38mm

1 box x 40 needles

Alcohol Swabs

1 box x 220 swabs

Sharps containers

3 individual sharps containers

Disposable dishes

6 individual dishes

Disposable Gloves

1 box x 110 gloves

Clinical waste bags and closure

devices

2 individual bags and closures

Sticking Plaster

1 box x 110 plasters

Alcohol Hand Rub

2 x 500mL bottles with

dispensers

Cotton Wool Balls

1 bag x 220 cotton wool balls

24 September

2009

Slide 88

Item

Quantity/Packaging

1mL syringes

1 box x 220 syringes

Drawing up needles 19g x 38mm

2 boxes x 44 needles

Injection needles 23g x 25mm

1 box x 200 needles

Drawing up needles 23g x 38mm

3 boxes x 40 needles

GP mini VacPac

24 September

2009

Slide 89

• Some additional quantities of each

component are provided to cover normal

levels of wastage that may occur in a mass

vaccination situation.

• The 19g x 38mm needles have been included

for drawing up along with the 23g x 38mm.

23g x 25mm needles can be used for

administering the vaccine to the majority of

the population.

• A quantity of 23g x 38mm needles has also

been provided for use with obese adults.

AND FINALLY

•Consent

24 September

2009

Slide 91

Child and Adult consent form

Containing the following:

- Fact sheet on the vaccine and what pandemic

influenza 2009 is

- Effects of the disease, possible side effects of

vaccination, contraindications and what to do to

reduce side effects

- Care after vaccination

- Pre vaccination checklist

- Client record following vaccination

24 September

2009

Slide 92

Documenting consent and reporting data

• Consent:

• All DoHWA health services should use the national

PANDEMIC (H1N1) 2009 INFLUENZA VACCINE

CONSENT FORM developed by DoHA. These will be

supplied or you may photocopy, or download from

website.

• GPs, ACCHOs, residential care facilities and other

non-government health services should obtain and

document informed consent for vaccination using

their usual procedure.

24 September

2009

Slide 93

• Data reporting:

• GPs, ACCHOs, residential care

facilities (metropolitan and regional) complete

the Pandemic Influenza Line List Form and fax

at end of each week to 9388 4820.

• Metropolitan mass vaccination clinics. A

CDCD staff member will visit your clinic daily

to collect original consent forms.

24 September

2009

Slide 94

• Metropolitan hospitals, workplace and other DoHWA

health services. Photocopy completed consent forms

and send the photocopied version with batch header

at end of each week via medical record courier

Panvax data entry, CDCD, 227 Stubbs Tce, Shenton

Park WA 2008 OR registered mail to Panvax data

entry, CDCD, PO Box 8172 Perth Business Centre

WA 6849.

 Regional DoHWA providers. Enter Panvax

vaccination date, batch number and reason for

vaccination on to HCARe and ensure that the patient

is registered on HCARe, as patient-identified data will

be downloaded periodically from HCARe and

uploaded into the statewide Panvax database.

24 September

2009

Slide 95

• A call centre will be organised which will act as a

help line to check to see if people have been

vaccinated i.e. which doses they have had. This

number is for health staff only!

• 1800 243 522

• 180 2007 – is for the general public

24 September

2009

Slide 96

Quick Consent – just a thought!

• It may be best to get clients together and do a group

consent prior to vaccination.

• I.E. 1 nurse to go through consent

- 1 admin to check to see it is filled and direct

any errors back to consent nurse (optional)

- then clients can see the vaccinator

• That way the vaccinator does not have to go through

the consent

24 September

2009

Slide 97

Trivalent vaccine

• To be included in the seasonal influenza

vaccine

• ?? Next year

24 September

2009

Slide 98

You will receive with each vaccine

order:

• Your vaccine

• Vacpacks

• Consent forms

• ADRAC (adverse events form)